RU2017104149A3 - - Google Patents
Info
- Publication number
- RU2017104149A3 RU2017104149A3 RU2017104149A RU2017104149A RU2017104149A3 RU 2017104149 A3 RU2017104149 A3 RU 2017104149A3 RU 2017104149 A RU2017104149 A RU 2017104149A RU 2017104149 A RU2017104149 A RU 2017104149A RU 2017104149 A3 RU2017104149 A3 RU 2017104149A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179048.5 | 2014-07-30 | ||
| EP14179048 | 2014-07-30 | ||
| PCT/EP2015/067098 WO2016016157A1 (en) | 2014-07-30 | 2015-07-27 | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017104149A RU2017104149A (ru) | 2018-08-28 |
| RU2017104149A3 true RU2017104149A3 (enExample) | 2019-02-28 |
| RU2703192C2 RU2703192C2 (ru) | 2019-10-15 |
Family
ID=51265507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017104149A RU2703192C2 (ru) | 2014-07-30 | 2015-07-27 | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10584385B2 (enExample) |
| EP (2) | EP3795695A1 (enExample) |
| JP (2) | JP6854752B2 (enExample) |
| KR (1) | KR102456013B1 (enExample) |
| CN (2) | CN114381512A (enExample) |
| CA (1) | CA2953483C (enExample) |
| ES (1) | ES2825675T3 (enExample) |
| IL (4) | IL290115B2 (enExample) |
| MX (2) | MX384679B (enExample) |
| PT (1) | PT3174995T (enExample) |
| RU (1) | RU2703192C2 (enExample) |
| WO (1) | WO2016016157A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| MX370538B (es) | 2013-03-27 | 2019-12-17 | Hoffmann La Roche | Marcadores genéticos para la predicción de respuesta a la terápia. |
| WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
| CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| US20190070178A1 (en) | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
| EP3696282A1 (en) * | 2019-02-14 | 2020-08-19 | Universidad del Pais Vasco | Method for diagnosing unstable atherosclerotic plaque |
| SG11202107468YA (en) | 2019-03-07 | 2021-08-30 | Dalcor Pharma Uk Ltd Leatherhead | Methods for treating or preventing heart failure and reducing risk of heart failure |
| WO2022264678A1 (ja) | 2021-06-16 | 2022-12-22 | 富士フイルム株式会社 | 内視鏡用粘膜下注入材 |
| CN113604560B (zh) * | 2021-08-25 | 2023-07-28 | 华中科技大学同济医学院附属协和医院 | 与血脂相关的snp及其应用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5952172A (en) | 1993-12-10 | 1999-09-14 | California Institute Of Technology | Nucleic acid mediated electron transfer |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| WO1997040462A2 (en) | 1996-04-19 | 1997-10-30 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| CA2303206A1 (en) | 1997-09-10 | 1999-03-18 | University Of Maryland, Baltimore | Method of amplifying dna and rna mismatch cleavage products |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| WO2000074471A1 (en) | 1999-06-04 | 2000-12-14 | Consejo Superior De Investigaciones Cientificas | Use of high oleic high stearic oils |
| US20030092647A1 (en) | 2001-08-08 | 2003-05-15 | Crooke Rosanne M. | Antisense modulation of cholesteryl ester transfer protein expression |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| US20030138444A1 (en) | 2001-08-18 | 2003-07-24 | Myriad Genetics, Incorporated | Composition and method for treating HIV infection |
| US20060141493A1 (en) | 2001-11-09 | 2006-06-29 | Duke University Office Of Science And Technology | Atherosclerotic phenotype determinative genes and methods for using the same |
| US20040180370A1 (en) | 2003-01-27 | 2004-09-16 | The Regents Of The University Of Colorado, A Body Corporate | Genetic diagnosis of alcoholism subtypes |
| BRPI0408442A (pt) | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
| TWI393560B (zh) | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| WO2005007628A1 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| KR20070087197A (ko) | 2003-09-26 | 2007-08-27 | 니뽄 다바코 산교 가부시키가이샤 | 잔여 리포프로테인 생산 저해 방법 |
| WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| HRP20070241T3 (hr) | 2003-12-19 | 2007-07-31 | Bristol-Myers Squibb Company | Azabiciklički heterocikli kao modulatori kanabinoid receptora |
| PT1697371E (pt) | 2003-12-19 | 2007-08-03 | Bristol Myers Squibb Co | Heterocíclos azabicíclicos como moduladores do receptor de canabinóides |
| US20050261201A1 (en) | 2004-03-30 | 2005-11-24 | Rejuvenon Corporation | Method of reducing C-reactive protein using growth hormone secretagogues |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| MX2007007188A (es) | 2004-12-18 | 2007-08-14 | Bayer Healthcare Ag | Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos. |
| WO2006072172A1 (en) | 2005-01-05 | 2006-07-13 | Medicure International Inc. | Compounds and methods for regulating triglyceride levels |
| WO2006099142A2 (en) * | 2005-03-10 | 2006-09-21 | The Trustees Of Boston University | Prognostic method for vascular diseases |
| JP2006288279A (ja) | 2005-04-11 | 2006-10-26 | Otsuka Pharmaceut Co Ltd | 出血時間延長傾向判定方法 |
| AU2006265975B2 (en) | 2005-07-01 | 2011-12-15 | Merck Sharp & Dohme Corp. | Process for synthesizing a CETP inhibitor |
| RU2008119687A (ru) | 2005-10-21 | 2009-11-27 | Новартис АГ (CH) | Комбинации органических соединений |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| BRPI0618379A2 (pt) | 2005-11-08 | 2011-08-30 | Ranbaxy Lab Ltd | processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico |
| US20070213274A1 (en) * | 2005-12-20 | 2007-09-13 | Oy Jurilab Ltd | Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C) |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| US20080221161A1 (en) | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| CA2684067A1 (en) | 2007-04-25 | 2008-11-06 | F. Hoffmann-La Roche Ag | Novel process for the preparation of acid chlorides |
| WO2009026241A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| ES2460900T3 (es) | 2008-04-04 | 2014-05-14 | F. Hoffmann-La Roche Ag | Nuevo procedimiento para la preparación de derivados de ácido ciclohexanocarboxílico mediante el correspondiente derivado ciclohexanocarboxamida |
| BRPI0909813B1 (pt) | 2008-04-04 | 2018-01-02 | F. Hoffmann-La Roche Ag | "processos para preparação de derivados de ácido ciclo-hexanocarboxílico, e intermediário" |
| KR101644222B1 (ko) | 2008-06-17 | 2016-07-29 | 에프. 호프만-라 로슈 아게 | 약학 활성 아미드의 제조에서 중간체로서의 1-(2-에틸-부틸)-사이클로헥산카복실산 에스터 |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| US20100183598A1 (en) | 2008-11-12 | 2010-07-22 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| WO2010066593A1 (en) | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
| US9682151B2 (en) | 2009-07-15 | 2017-06-20 | The Regents Of The University Of California | Peptides whose uptake in cells is controllable |
| CN102844434A (zh) * | 2010-04-07 | 2012-12-26 | Isis制药公司 | Cetp表达的调节 |
| WO2012012870A1 (en) * | 2010-07-28 | 2012-02-02 | Institut De Cardiologie De Montreal | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex |
| CA2809215A1 (en) | 2010-09-16 | 2012-03-22 | F. Hoffmann-La Roche Ag | New process |
| MY164729A (en) | 2010-11-04 | 2018-01-30 | Hoffmann La Roche | A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium |
| WO2012069087A1 (en) | 2010-11-25 | 2012-05-31 | Mediasuccess Gmbh | Automatic text generation |
| BR112013014291A2 (pt) | 2010-12-08 | 2016-09-20 | Hoffmann La Roche | formulação lipossômica de calcetrapib |
| BR112013014029B1 (pt) | 2010-12-16 | 2021-07-20 | F. Hoffmann-La Roche Ag | Processo para a preparação de derivados de tiol aromático por hidrogenação de dissulfetos |
| US20140044668A1 (en) * | 2011-02-15 | 2014-02-13 | The Ohio State University | Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs |
| CN103391769A (zh) * | 2011-02-17 | 2013-11-13 | 霍夫曼-拉罗奇有限公司 | 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法 |
| US9664698B2 (en) | 2011-04-08 | 2017-05-30 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| US20140162376A1 (en) * | 2011-04-29 | 2014-06-12 | Michael N. Oda | Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport |
| US20120301439A1 (en) | 2011-05-24 | 2012-11-29 | Washington University | Inhibition of choroidal neovascularization |
| US8975438B2 (en) | 2011-07-13 | 2015-03-10 | Hoffmann-La Roche Inc. | Process for the preparation of cyclohexanecarboxylic acid derivatives |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| JP6080226B2 (ja) | 2012-03-06 | 2017-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン |
| BR112014027047A2 (pt) | 2012-04-30 | 2017-06-27 | Hoffmann La Roche | nova formulação |
| MX351059B (es) | 2012-08-17 | 2017-09-29 | Laboratorios Senosiain S A De C V Star | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. |
| MX370538B (es) | 2013-03-27 | 2019-12-17 | Hoffmann La Roche | Marcadores genéticos para la predicción de respuesta a la terápia. |
| BR112016013923A2 (pt) | 2013-12-19 | 2017-08-08 | Hoffmann La Roche | Modulador de cetp para o uso no tratamento de enfermidade ocular |
| GB201401617D0 (en) * | 2014-01-30 | 2014-03-19 | Helperby Therapeutics Ltd | Novel combination and use |
| WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
| US20190070178A1 (en) | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
| JP2021534236A (ja) | 2018-08-09 | 2021-12-09 | ダルコア ファーマ ユーケー リミテッド，レザーヘッド，ツーク ブランチ | 新規発症２型糖尿病の発生遅延並びに２型糖尿病の進行緩徐化及び治療の方法 |
-
2015
- 2015-07-27 WO PCT/EP2015/067098 patent/WO2016016157A1/en not_active Ceased
- 2015-07-27 IL IL290115A patent/IL290115B2/en unknown
- 2015-07-27 CN CN202210024117.8A patent/CN114381512A/zh active Pending
- 2015-07-27 EP EP20184540.1A patent/EP3795695A1/en not_active Withdrawn
- 2015-07-27 PT PT157422502T patent/PT3174995T/pt unknown
- 2015-07-27 IL IL300472A patent/IL300472B2/en unknown
- 2015-07-27 RU RU2017104149A patent/RU2703192C2/ru active
- 2015-07-27 EP EP15742250.2A patent/EP3174995B1/en active Active
- 2015-07-27 JP JP2017504647A patent/JP6854752B2/ja active Active
- 2015-07-27 MX MX2017000582A patent/MX384679B/es unknown
- 2015-07-27 ES ES15742250T patent/ES2825675T3/es active Active
- 2015-07-27 CN CN201580040416.9A patent/CN106559998B/zh active Active
- 2015-07-27 CA CA2953483A patent/CA2953483C/en active Active
- 2015-07-27 KR KR1020177002272A patent/KR102456013B1/ko active Active
-
2017
- 2017-01-13 MX MX2021006626A patent/MX2021006626A/es unknown
- 2017-01-25 US US15/415,112 patent/US10584385B2/en active Active
- 2017-01-26 IL IL250308A patent/IL250308B/en active IP Right Grant
-
2020
- 2020-01-27 US US16/773,040 patent/US11401554B2/en active Active
-
2021
- 2021-03-16 JP JP2021042828A patent/JP7244560B2/ja active Active
- 2021-03-30 IL IL281905A patent/IL281905B/en unknown
-
2022
- 2022-06-16 US US17/842,282 patent/US12371748B2/en active Active